Huntsville, Alabama 35801

  • Acute Coronary Syndrome


This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.


Inclusion Criteria: - Male or female least 18 years of age - Evidence of myocardial necrosis, consistent with type I (spontaneous) MI - No suspicion of acute kidney injury - Evidence of multivessel coronary artery disease - Presence of established cardiovascular risk factor(s): 1. Diabetes mellitus on pharmacotherapy OR 2. 2 or more of the following: age ≥ 65 years, prior history of MI, peripheral arterial disease Exclusion Criteria: - Ongoing hemodynamic instability - Evidence of hepatobiliary disease - Evidence of severe chronic kidney disease - Plan to undergo scheduled coronary artery bypass graft surgery as treatment for the index MI - Known history of allergies, hypersensitivity, or deficiencies to soy bean, peanut or albumin



Primary Contact:

Study Director
Danielle Duffy, MD
CSL Behring - Sr Global Clinical Program Dir - CV & Metabolism

Trial Registration Coordinator
Phone: 610-878-4000

Backup Contact:


Location Contact:

Huntsville, Alabama 35801
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.